Barriers to new drug development in respiratory disease

摘要: Despite enormous unmet medical needs in respiratory medicine, very few new classes of safe and effective therapy have been introduced over the past 40 years. In spite its burden, medicine appears to fewer approved therapies than other common disease areas, such as cardiovascular, metabolic neurological diseases, with drug candidates a higher failure rate. Furthermore, areas discovery, time for development is getting longer risk ever higher, leading growing costs. order identify some barriers discovery European Respiratory Society Presidential Summit was held on July 2–3, 2014, Rome, Italy. This meeting brought together scientists, clinicians, regulators, clinical pharmacologists pharmaceutical industry from across Europe explore how these might be overcome facilitate future diseases. editorial highlights opportunities improving that were discussed at 2014 Summit. These include more predictive preclinical models, regulatory framework needed better development, Germany hoping address issues above through recently established national centre lung research. The ERS discusses drugs can accelerated